نتایج جستجو برای: lowdensity lipoprotein ldl

تعداد نتایج: 66227  

Journal: :Arteriosclerosis, thrombosis, and vascular biology 2012
Eric J Olson Gregory L Pearce Nigel P Jones Dennis L Sprecher

OBJECTIVE Peroxisome proliferator-activated receptor-δ-induced upregulation in skeletal muscle fatty acid oxidation would predict the modulation of lipid/lipoproteins. METHODS AND RESULTS GW501516 (2.5, 5.0, or 10.0 mg) or placebo was given for 12 weeks to patients (n=268) with high-density lipoprotein (HDL) cholesterol <1.16 mmol/L. Fasting lipids/apolipoproteins (apos), insulin, glucose, an...

Journal: :Arteriosclerosis, thrombosis, and vascular biology 2004
A M Georgieva M M J van Greevenbroek R M Krauss M C G J Brouwers V M M-J Vermeulen M G Robertus-Teunissen C J H van der Kallen T W A de Bruin

OBJECTIVE The present study addresses the presence of distinct metabolic phenotypes in familial combined hyperlipidemia (FCHL) in relation to small dense low-density lipoprotein (sd LDL) and very low-density lipoprotein (VLDL) subclasses. METHODS AND RESULTS Hyperlipidemic FCHL relatives (n=72) were analyzed for LDL size by gradient gel electrophoresis. Pattern B LDL (sd LDL, particle size <2...

Journal: :Biophysical Journal 2021

Understanding the chemical nature of biomarkers and their interaction with host environment is critical to both development implementation diagnostic tools therapeutics. Human lipoproteins, such as high-density lipoprotein (HDL) low-density (LDL), are important carrier molecules for transporting cholesterol other lipid organs where they can be processed. These lipoproteins have more recently be...

Journal: :Kidney international 2009
George A Kaysen

High-density lipoprotein (HDL) cholesterol level is low in dialysis patients. The HDL that is present is dysfunctional, failing to protect low-density lipoprotein (LDL) from oxidation and reduce levels of oxidized LDL. Addition of the orally absorbable amphipathic peptide 4-F to LDL obtained from dialysis patients protects LDL from oxidation in vitro and reduces the capacity of oxidized LDL to ...

2013
Montserrat Estruch Jose Luis Sanchez-Quesada Lorea Beloki Jordi Ordoñez-Llanos Sonia Benitez

Electronegative low-density lipoprotein (LDL(-)) is a minor modified LDL subfraction that is present in blood. LDL(-) promotes inflammation and is associated with the development of atherosclerosis. We previously reported that the increase of cytokine release promoted by this lipoprotein subfraction in monocytes is counteracted by high-density lipoprotein (HDL). HDL also inhibits a phospholipas...

Journal: :Blood 1998
S Rota N A McWilliam T P Baglin C D Byrne

The importance of lipoproteins in the etiology of atherosclerosis is well established. Evidence is now accumulating to implicate thrombin in the pathogenesis of atherosclerosis. We have investigated whether atherogenic lipoproteins can support thrombin generation. In the absence of platelets or endothelial cells, both very low-density lipoprotein (VLDL) and oxidized low-density lipoprotein (LDL...

Journal: :The Journal of clinical investigation 1978
L K Curtiss T S Edgington

The present study demonstrates the existence on human peripheral blood lymphocytes of a saturable cell surface receptor for low density lipoprotein inhibitor (LDL-In), a subset of normal human serum low density lipoprotein (LDL) that has been previously demonstrated to suppress selected lymphocyte functions in vivo and in vitro. The binding of radioiodinated LDL-In of demonstrable biological ac...

Journal: :Arteriosclerosis, thrombosis, and vascular biology 1998
M Klouche S Gottschling V Gerl W Hell M Husmann B Dorweiler M Messner S Bhakdi

The mechanisms underlying the selective accumulation of macrophages in early atherosclerotic lesions are poorly understood but are likely to be related to specific properties of altered low density lipoprotein (LDL) deposited in the subendothelium. Enzymatic, nonoxidative degradation of LDL converts the lipoprotein to a potentially atherogenic moiety, enzymatically altered LDL (E-LDL), which ac...

Journal: :Clinical science and molecular medicine 1976
P N Durrington C J Roberts L Jackson R A Branch M Hartog

1. Phenobarbitone in a dose of 180 mg daily was administered to ten normal subjects for 3 weeks. There was a significant increase in total plasma cholesterol, plasma low-density-lipoprotein cholesterol, plasma low-density-lipoprotein (LDL) triglycerides and plasma LDL protein. The increase in plasma LDL cholesterol accounted for the increase in total plasma cholesterol. There was a significant ...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید